Taiwan’s healthcare system benefits from more than 20 years of universal access to healthcare, which has helped to create a comprehensive set of data available to researchers. Health technology assessment has been in place in parts of the system for more than a decade.
Although there are increasing efforts to introduce cost-effectiveness and broader measures of “value” into analysis and decision-making about new medical treatments, there has been no effort so far to accept either a common understanding of value, or a standardised approach toward evaluating healthcare with regard to this measure.
How can Taiwan better integrate the concept of value into its healthcare system?